Search Results

You are looking at 111 - 120 of 370 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger

metastatic colon cancer. The Use of Biologic Agents in the Older Population Bevacizumab The addition of the vascular endothelial growth factor antibody bevacizumab has been shown to improve progression-free and overall survivals among patients

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

metastatic colorectal cancer treated with cetuximab . Ann Oncol 2008 ; 19 : 508 – 515 . 28 Punt CJ Tol J Rodenburg CJ . Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal

Full access

Lainie Martin and Russell J. Schilder

. The safety of bevacizumab . Expert Opin Drug Saf 2006 ; 5 : 289 – 301 . 13. Jain RK . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy . Nat Med 2001 ; 7 : 987 – 989 . 14

Full access

Harold J. Burstein

approval, MSKCC staff called the decision a “no brainer.” The median survival benefit with the drug was minimal (1.4 months); the drug has a similar mechanism of action to bevacizumab, which is already available for advanced colorectal cancer; and the drug

Full access

Tanios Bekaii-Saab

] +/- panitumumab in first-line treatment of mCRC) suggests that the presence of these additional RAS mutations predict for lack of benefit. Data from the large phase II randomized study PEAK (FOLFOX plus panitumumab vs FOLFOX plus bevacizumab in first

Full access

Jonas A. de Souza, Mark J. Ratain, and A. Mark Fendrick

, bevacizumab is the same price per milligram for patients with metastatic colorectal cancer (5 mg/kg every 2 weeks), in whom it provides a median overall survival benefit of 4.7 months 16 (hazard ratio [HR] for death, 0.66; 95% CI, 0.54-0.81; P < .001), as

Full access

Presenter: Robert I. Haddad

According to Dr. Haddad, other research looking at targets besides immunotherapy has been “disappointing.” A long-running phase III trial of chemotherapy with or without bevacizumab in patients with recurrent/metastatic HNSCC showed no statistically

Full access

Denise Leung, Xiaosi Han, Tom Mikkelsen, and L. Burt Nabors

/print certificate. Release date: November 4, 2014; Expiration date: November 4, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Describe the challenges of MRI assessment in patients receiving bevacizumab

Full access

Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt, and Benjamin R. Tan

erlotinib plus bevacizumab. Response to Gemcitabine-Based Treatments A total of 88% of patients (50/57) who received a gemcitabine-based regimen were evaluable for response ( Table 2 ), including 37 of 41 patients who received gemcitabine

Full access

Matthias Holdhoff and Marc C. Chamberlain

trial. 35 The results of AVAglio and RTOG 0825, 2 studies examining the addition of bevacizumab to radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, were recently presented. 39 , 40 Neither study showed an OS advantage with